Production (Stage)
Qualigen Therapeutics, Inc.
QLGN
$3.42
-$0.10-2.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1,086.55% | -83.64% | |||
| Gross Profit | 1,086.55% | 83.64% | |||
| SG&A Expenses | -11.11% | 16.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.30% | -27.13% | |||
| Operating Income | 23.30% | 27.13% | |||
| Income Before Tax | 52.66% | -21.55% | |||
| Income Tax Expenses | 350.00% | -83.33% | |||
| Earnings from Continuing Operations | 52.30% | -21.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 52.30% | -13.80% | |||
| EBIT | 23.30% | 27.13% | |||
| EBITDA | 23.32% | 27.14% | |||
| EPS Basic | 76.81% | 54.70% | |||
| Normalized Basic EPS | 89.89% | 44.67% | |||
| EPS Diluted | 76.81% | 54.70% | |||
| Normalized Diluted EPS | 89.89% | 44.67% | |||
| Average Basic Shares Outstanding | 102.55% | 155.03% | |||
| Average Diluted Shares Outstanding | 102.55% | 155.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||